Beta Bionics, Inc. (BBNX) stock
BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/306% above fair value
$16.42−0.09 (-0.55%)
Close on Nov 13, 2026Market cap $892.71MP/E –Yield –
Beta Bionics operating margin
Operating margin is operating income as a percentage of revenue.
Beta Bionics's operating margin for the twelve months ending Sep 30, 2026 was -72.7%. For fiscal 2025 it was -71.5%, against -69.5% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -71.5% | −2.0 |
| FY2024 | Dec 31, 2024 | -69.5% | +229.4 |
| FY2023 | Dec 31, 2023 | -298.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -74.9% | −12.4 |
| Q2 FY2026 | Jun 30, 2026 | -79.9% | +5.6 |
| Q1 FY2026 | Mar 31, 2026 | -87.9% | +17.8 |
| Q4 FY2025 | Dec 31, 2025 | -50.2% | +13.6 |
| Q3 FY2025 | Sep 30, 2025 | -62.5% | +3.2 |
| Q2 FY2025 | Jun 30, 2025 | -85.5% | −7.2 |
| Q1 FY2025 | Mar 31, 2025 | -105.7% | −32.6 |
| Q4 FY2024 | Dec 31, 2024 | -63.8% | – |
| Q3 FY2024 | Sep 30, 2024 | -65.7% | – |
| Q2 FY2024 | Jun 30, 2024 | -78.3% | – |
| Q1 FY2024 | Mar 31, 2024 | -73.1% | – |
See a number that looks wrong?